- Home
- SNGX vs VIVS Comparison
SNGX vs VIVS Comparison
Compare SNGX & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- VIVS
- Stock Information
- Founded
- SNGX 1987
- VIVS 2007
- Country
- SNGX United States
- VIVS United States
- Employees
- SNGX N/A
- VIVS N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNGX Health Care
- VIVS Health Care
- Exchange
- SNGX Nasdaq
- VIVS Nasdaq
- Market Cap
- SNGX 10.1M
- VIVS 8.1M
- IPO Year
- SNGX 1987
- VIVS N/A
- Fundamental
- Price
- SNGX $1.64
- VIVS $2.83
- Analyst Decision
- SNGX Strong Buy
- VIVS
- Analyst Count
- SNGX 1
- VIVS 0
- Target Price
- SNGX $6.00
- VIVS N/A
- AVG Volume (30 Days)
- SNGX 2.9M
- VIVS 77.6K
- Earning Date
- SNGX 11-07-2025
- VIVS 11-07-2025
- Dividend Yield
- SNGX N/A
- VIVS N/A
- EPS Growth
- SNGX N/A
- VIVS N/A
- EPS
- SNGX N/A
- VIVS N/A
- Revenue
- SNGX N/A
- VIVS $142,000.00
- Revenue This Year
- SNGX N/A
- VIVS $42.38
- Revenue Next Year
- SNGX N/A
- VIVS $15.42
- P/E Ratio
- SNGX N/A
- VIVS N/A
- Revenue Growth
- SNGX N/A
- VIVS 94.52
- 52 Week Low
- SNGX $1.09
- VIVS $1.41
- 52 Week High
- SNGX $6.23
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- VIVS 46.40
- Support Level
- SNGX $1.60
- VIVS $2.69
- Resistance Level
- SNGX $1.97
- VIVS $3.54
- Average True Range (ATR)
- SNGX 0.16
- VIVS 0.32
- MACD
- SNGX 0.06
- VIVS -0.11
- Stochastic Oscillator
- SNGX 61.63
- VIVS 16.54
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.